{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Thyroid+Gland+Carcinoma&page=2", "query": { "condition": "Unresectable Thyroid Gland Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Thyroid+Gland+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T04:05:00.665Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04171622", "title": "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Thyroid Gland Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8", "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8", "Thyroid Gland Squamous Cell Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-11-04", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04171622" }, { "nct_id": "NCT01683110", "title": "Expanded Access of Cabozantinib in Medullary Thyroid Cancer", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Medullary Thyroid Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 5, "location_summary": "Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683110" }, { "nct_id": "NCT03181100", "title": "Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Thyroid Gland Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8", "Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8", "Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8", "Thyroid Gland Anaplastic Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2017-07-27", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03181100" }, { "nct_id": "NCT02012231", "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Thyroid Cancer", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Histiocytosis", "Hairy Cell Leukemia" ], "interventions": [ { "name": "PLX8394", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fore Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-02", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012231" }, { "nct_id": "NCT02973997", "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Columnar Cell Variant Thyroid Gland Papillary Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Follicular Carcinoma", "Recurrent Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Hurthle Cell Carcinoma", "Unresectable Differentiated Thyroid Gland Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib Mesylate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2018-02-07", "completion_date": "2023-10-08", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 7, "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973997" }, { "nct_id": "NCT00028496", "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Rectum", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Male Breast Cancer", "Mixed Adenocarcinoma of the Stomach", "Ovarian Endometrioid Adenocarcinoma", "Paget Disease of the Breast With Intraductal Carcinoma", "Paget Disease of the Breast With Invasive Ductal Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Salivary Gland Adenocarcinoma", "Stage II Malignant Testicular Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox GM-CSF vaccine adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028496" }, { "nct_id": "NCT00389441", "title": "Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Neoplasms" ], "interventions": [ { "name": "AG-013736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2006-12", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 10, "location_summary": "Orange, California • Aurora, Colorado • Tampa, Florida + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389441" }, { "nct_id": "NCT00027534", "title": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "TRICOM-CEA(6D)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Michael Morse, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2002-01", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027534" }, { "nct_id": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anaplastic Thyroid Cancer", "Insular Thyroid Cancer", "Metastatic Parathyroid Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Parathyroid Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Thyroid Cancer", "Recurrent Verrucous Carcinoma of the Larynx", "Stage III Follicular Thyroid Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Non-small Cell Lung Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVA Basal Cell Carcinoma of the Lip", "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Lymphoepithelioma of the Oropharynx", "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVA Papillary Thyroid Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVB Basal Cell Carcinoma of the Lip", "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Lymphoepithelioma of the Oropharynx", "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVB Papillary Thyroid Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVC Basal Cell Carcinoma of the Lip", "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Lymphoepithelioma of the Oropharynx", "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVC Papillary Thyroid Cancer", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Thryoid Gland Nonmedullary Carcinoma", "Thyroid Gland Medullary Carcinoma", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068497" }, { "nct_id": "NCT00381641", "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Thyroid Gland Oncocytic Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2006-08-29", "completion_date": "2024-12-10", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-05-22T04:05:00.665Z", "location_count": 17, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381641" } ] }